TRCT
BIVI icon

Tower Research Capital (TRC)’s BioVie BIVI Stock Holding History

Tower Research Capital (TRC)’s Portfolio BIVI Stock Details BIVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.6K Buy
7,540
+6,923
+1,122% +$8.89K ﹤0.01% 3882
2025
Q4 		$716 Buy
+617
New +$993 ﹤0.01% 4836
2025
Q3 		– Sell
-462
Closed -$4.27K – 5232
2025
Q2 		$4.27K Sell
462
-79
-15% -$780 ﹤0.01% 4351
2025
Q1 		$5.3K Buy
541
+345
+176% +$5.51K ﹤0.01% 4134
2024
Q4 		$3.91K Sell
196
-132
-40% -$3.18K ﹤0.01% 4565
2024
Q3 		$3.94K Buy
328
+114
+53% +$3.63K ﹤0.01% 4734
2024
Q2 		$8.57K Buy
214
+91
+74% +$4.36K ﹤0.01% 4333
2024
Q1 		$6.5K Buy
123
+50
+68% +$5.13K ﹤0.01% 4359
2023
Q4 		$9.17K Sell
73
-148
-67% -$44.5K ﹤0.01% 4426
2023
Q3 		$75.3K Buy
221
+156
+240% +$61K ﹤0.01% 2205
2023
Q2 		$28.2K Buy
65
+22
+51% +$14.8K ﹤0.01% 3083
2023
Q1 		$35K Buy
43
+41
+2,050% +$27.2K ﹤0.01% 2834
2022
Q4 		$1K Sell
2
-57
-97% -$30.8K ﹤0.01% 5553
2022
Q3 		$15K Buy
59
+17
+40% +$4.04K ﹤0.01% 4156
2022
Q2 		$6K Buy
42
+34
+425% +$10.2K ﹤0.01% 4896
2022
Q1 		$4K Buy
+8
New +$2.95K ﹤0.01% 5180
2021
Q2 		– Sell
-3
Closed -$5K – 5472
2021
Q1 		$5K Buy
+3
New +$8.56K ﹤0.01% 4650

Other funds holding BIVI

DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Tower Research Capital (TRC)'s BIVI Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its BioVie (BIVI) stake by 1,122% in Q1 2026, buying an estimated $8.89K and bringing the position to 7,540 shares worth $10.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3882.

Tower Research Capital (TRC) first reported a position in BIVI in Q1 2021 and has held it in 17 quarters since. The position peaked at $75.3K in Q3 2023. 33 funds tracked by Wall St. Rank hold BIVI as of Q1 2026.

  • Tower Research Capital (TRC) held 7,540 shares of BioVie worth $10.6K as of Q1 2026.
  • Tower Research Capital (TRC) bought 6,923 BioVie shares in Q1 2026, an estimated $8.89K.
  • BioVie made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3882 holding.
  • Tower Research Capital (TRC) first reported a position in BioVie in Q1 2021 and has held it in 17 quarters since.
  • Tower Research Capital (TRC)'s BioVie position peaked at $75.3K in Q3 2023.
  • 33 funds tracked by Wall St. Rank held BioVie as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.